PEPperPRINT GmbH
PEPperPRINT GmbH is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at PEPperPRINT GmbH.
PEPperPRINT GmbH is a company.
Key people at PEPperPRINT GmbH.
Key people at PEPperPRINT GmbH.
# PEPperPRINT GmbH: High-Level Overview
PEPperPRINT is a biotech company that develops and provides high-density peptide microarray technology and related services for immune response analysis.[1] Founded in 2001 as a spin-off from the German Cancer Research Center (DKFZ) in Heidelberg, Germany, the company serves researchers and pharmaceutical organizations globally by enabling detailed characterization of antibody responses and epitope mapping.[2]
The company addresses a critical research challenge: understanding how antibodies bind to specific protein targets (epitopes) with amino-acid resolution. PEPperPRINT's proprietary laser printing technology converts protein sequences into highly overlapping peptide libraries on glass slides, allowing scientists to identify which parts of a protein trigger immune responses.[7] This capability is essential for vaccine development, biomarker discovery, cancer research, autoimmune disease studies, and therapeutic antibody characterization.[4]
# Origin Story
PEPperPRINT was founded in 2001 by Frank Breitling and Ralf Bischoff as an intellectual property platform emerging from the research group "Chip-based Peptide Libraries" led by Nobel Prize laureate Prof. Dr. Harald zur Hausen at the German Cancer Research Center.[2] The founding team expanded in 2002 when Volker Stadler and Frieder Breitling joined, assembling a multidisciplinary group with expertise in physics, chemistry, engineering, and biology.
The company's breakthrough innovation—combinatorial synthesis of high-density peptide microarrays using amino acid toner particles and a custom 24-color laser printer—was published in *Science* in 2007, earning PEPperPRINT the German Science Stifter Prize.[2] The company became operationally active in April 2010 following a Series A funding round from High-Tech Gründerfonds and receipt of the Innovation Award of German Industry.[2] Production launched in early 2011 using second-generation laser printers manufactured by Fraunhofer IPA and KMS Automation, followed by the introduction of complementary services like PEPperMAP® Epitope Mapping and Serum Profiling.[2]
# Core Differentiators
# Role in the Broader Tech Landscape
PEPperPRINT operates at the intersection of immunology research acceleration and precision medicine development. The company's technology addresses a fundamental bottleneck in drug development and vaccine design: the need to understand immune responses at molecular resolution.
The timing is particularly significant given the post-pandemic emphasis on rapid vaccine development, the growing importance of personalized medicine, and increased investment in cancer immunotherapy and autoimmune disease research.[4] PEPperPRINT's microarray platform enables researchers to move beyond traditional antibody characterization methods, reducing time and cost while increasing scientific depth.
The company influences the broader ecosystem by democratizing access to high-resolution epitope mapping—capabilities previously limited to well-funded institutions. By serving universities, biotech companies, and pharmaceutical firms globally, PEPperPRINT accelerates discovery across multiple therapeutic areas and research domains.[6]
# Quick Take & Future Outlook
PEPperPRINT has established itself as the market leader in peptide microarray technology through sustained innovation and scientific validation. The June 2025 launch of cLIFT technology signals the company's commitment to pushing technical boundaries—doubling peptide density while expanding chemistry compatibility represents a significant competitive moat.
Looking forward, PEPperPRINT is well-positioned to capitalize on several converging trends: the shift toward precision medicine, increased demand for biomarker discovery in oncology and immunology, and the growing need for comprehensive antibody characterization in therapeutic development. The expansion into T-cell epitope mapping broadens the company's addressable market beyond B-cell focused research.
The company's trajectory suggests continued growth through both organic expansion of its service offerings and potential strategic partnerships with pharmaceutical and biotech firms seeking to accelerate their immunological research capabilities. As personalized medicine and immunotherapy become increasingly central to drug development, PEPperPRINT's technology will likely become even more integral to the research pipeline.
